2024年7月6日 · Immune engineering and modulation are the basis of a novel but powerful tool to treat immune diseases using virus-like particles (VLPs). VLPs are formed by the viral capsid without genetic material making them non-infective.

2023年8月19日 · In this review, we summarize the VLP cancer vaccines successfully licensed or under development for the prevention of cancer caused by viral infections, as well as the VLP vaccines under preclinical or early clinical evaluation as therapeutic strategy for various cancer types, with a focus on HER-2-positive breast cancer models.

2024年12月12日 · VLP-based mucosal vaccines offer a compelling strategy for controlling infectious diseases that enter the body through mucosal surfaces. The ability of VLPs to carry multiple antigens could be exploited further to design vaccines that target several mucosal pathogens simultaneously.

Virus-like particles (VLPs) are self-assembled nanoparticles whose intrinsic properties, such as heterogeneity, and highly ordered structural organization are exploited to prepare vaccines; imaging agents; construct nanobioreactors; cancer treatment approaches; or …

VLP from the foot-and-mouth disease virus (FMDV), which was loaded with the anticancer drug doxorubicin (DOX), can deliver the drug into HeLa cells via the RGD motif binding to the integrin receptor sitting on the surface of tumor cells, and the anti-tumor experiment in mice demonstrated the high tumor killing efficacy of DOX-loaded VLPs ...

Virus-like particles (VLPs) are empty, nanoscale structures morphologically resembling viruses. Internal cavity, noninfectious, and particulate nature with a high density of repeating epitopes, make them an ideal platform for vaccine development and drug delivery.

2010年5月2日 · We chemically coupled PvTRAP to VLPs derived from the cucumber mosaic virus fused to a universal T-cell epitope of the tetanus toxin (CMVtt), formulated with MCT and compared the induced immune responses to PvTRAP formulated in PBS or Alum. The protective capacity of the various formulations was assessed using …

2023年3月31日 · VLPs produced using recombinant protein expression systems can stimulate strong B- and T-cell immune responses, have been shown to exhibit self-adjuvanting abilities …

2024年6月8日 · Various immunization approaches revealed that pCap3-Cap2E VLP vaccines were capable of activating high PCV3 Cap-specific antibody levels and effectively neutralizing both PCV3 and PCV2. Furthermore, pCap3-Cap2E VLPs demonstrated a potent ability to activate cellular immunity, protecting against PCV3 infection and preventing lung damage in mice.

2021年8月18日 · In this study, we developed SARS-CoV-2 virus-like particles (VLPs) containing the full length of spike (S) glycoprotein (S full), S1, or S2 together with the influenza matrix protein 1 (M1) as a core protein.